Related Experiment Videos
Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group
J Thomas1, B de Pauw, A Hagenbeek
1Division of Oncology, University Hospital, St Rafaël, Leuven, Belgium.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Abstract:
Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.